Cite
HARVARD Citation
Takaoka, Y. et al. (2021). Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. Hepatology research. 51 (1), pp. 51-61. [Online].